Next Article in Journal
Complexes of the Mycotoxins Citrinin and Ochratoxin A with Aluminum Ions and their Spectroscopic Properties
Previous Article in Journal
Post-Harvest Contamination with Mycotoxins in the Context of the Geographic and Agroclimatic Conditions in Romania
Correction published on 13 February 2019, see Toxins 2019, 11(2), 115.
Article

AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

1
Ipsen Bioinnovation, Abingdon OX14 4RY, UK
2
Ipsen Pharma, Cambridge, MA 02142, USA
3
TNO—CBRN Protection, 2288GJ Rijswijk, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 18 October 2018 / Revised: 5 December 2018 / Accepted: 11 December 2018 / Published: 13 December 2018
Botulinum neurotoxin type-A (BoNT-A) blocks the release of acetylcholine from peripheral cholinergic nerve terminals and is an important option for the treatment of disorders characterised by excessive cholinergic neuronal activity. Several BoNT-A products are currently marketed, each with unique manufacturing processes, excipients, formulation, and non-interchangeable potency units. Nevertheless, the effects of all the products are mediated by the 150 kDa BoNT-A neurotoxin. We assessed the quantity and light chain (LC) activity of BoNT-A in three commercial BoNT-A products (Dysport®; Botox®; Xeomin®). We quantified 150 kDa BoNT-A by sandwich ELISA and assessed LC activity by EndoPep assay. In both assays, we assessed the results for the commercial products against recombinant 150 kDa BoNT-A. The mean 150 kDa BoNT-A content per vial measured by ELISA was 2.69 ng/500 U vial Dysport®, 0.90 ng/100 U vial Botox®, and 0.40 ng/100 U vial Xeomin®. To present clinically relevant results, we calculated the 150 kDa BoNT-A/US Food and Drug Administration (FDA)-approved dose in adult upper limb spasticity: 5.38 ng Dysport® (1000 U; 2 × 500 U vials), 3.60 ng Botox® (400 U; 4 × 100 U vials), and 1.61 ng Xeomin® (400 U; 4 × 100 U vials). EndoPep assay showed similar LC activity among BoNT-A products. Thus, greater amounts of active neurotoxin are injected with Dysport®, at FDA-approved doses, than with other products. This fact might explain the long duration of action reported across multiple indications, which benefits patients, caregivers, clinicians, and healthcare systems. View Full-Text
Keywords: botulinum toxin; BoNT; spasticity; Dysport®, abobotulinumtoxinA; glabellar lines botulinum toxin; BoNT; spasticity; Dysport®, abobotulinumtoxinA; glabellar lines
Show Figures

Figure 1

MDPI and ACS Style

Field, M.; Splevins, A.; Picaut, P.; Van der Schans, M.; Langenberg, J.; Noort, D.; Foster, K. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins 2018, 10, 535. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins10120535

AMA Style

Field M, Splevins A, Picaut P, Van der Schans M, Langenberg J, Noort D, Foster K. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018; 10(12):535. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins10120535

Chicago/Turabian Style

Field, Malgorzata; Splevins, Andrew; Picaut, Philippe; Van der Schans, Marcel; Langenberg, Jan; Noort, Daan; Foster, Keith. 2018. "AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients" Toxins 10, no. 12: 535. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins10120535

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop